NCT02973893 - Study of VF001-DP in Patients With Chronic Venous Leg Ulcers | Biotech Hunter

Enrollment

156

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

February 28, 2019

Conditions

UlcerLeg UlcerVaricose UlcerPathologic ProcessesSkin UlcerSkin DiseasesVascular DiseasesCardiovascular Diseases

Interventions

BIOLOGICAL

Placebo

BIOLOGICAL

VF001-DP LD

VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.

BIOLOGICAL

VF001-DP HD

VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.

Trial Locations (17)

19610

Center for Advanced Wound Care PC, Wyomissing

24012

Alliance Research Centers, Laguna Hills

27599

University of North Carolina - Chapel Hill, Chapel Hill

33136

University of Miami Hospital, Miami

33143

Doctor Research Network (Dr Hanft), Miami

33169

Barry University School of Podiatric Medicine, North Miami Beach

33176

Miami Dade Medical Research Center (Dr Oliva), Miami

Spotlight Research Centre, Miami

89119

Advanced Foot and Ankle Center, Las Vegas

90057

Foot and Ankle Clinic, Los Angeles

92130

ILD Research Center, Carlsbad

93721

Limb Preservation Platform, Inc., Fresno

94115

Bay Area Foot Care, San Francisco

94553

Center for Clinical Research, Martinez

94705

Bay Area Foot Care, San Francisco

95628

Sacramento Foot Ankle Cente, Sacramento

95687

NorthBay Center for Wound Care, Vacaville